Skip to main content

Table 1 Baseline patient and control characteristics

From: Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis

 

Patients (n = 141)

Control subjects (n = 141)

p Values

Age, years

54 (45–61)

54 (45–61)

0.96

Women

114 (80.9)

114 (80.9)

1.0

Disease duration, years

6.8 (3.0–14.9)

  

RF-positive

100 (70.9)

  

Anti-CCP-positive

109 (77.3)

  

Using methotrexate

109 (77.3)

  

Using prednisolone

78 (55.3)

  

Biologic DMARD at inclusion

 Infliximab

13 (9.2)

  

 Etanercept

56 (39.7)

  

 Adalimumab

6 (4.3)

  

 Golimumab

8 (5.7)

  

 Certolizumab

11 (7.8)

  

 Rituximab

32 (22.7)

  

 Abatacept

3 (2.1)

  

 Tocilizumab

12 (8.5)

  

Patient’s global VAS, 0–100

46 (20–67)

  

Assessor’s global VAS, 0–100

27 (18–38)

  

Number of tender joints (of 32)

4 (2–11)

  

Number of swollen joints (of 32)

6 (3–11)

  

DAS28(ESR)

4.4 (1.4)a

  

Sum GS US score

27 (17–43)

  

Sum PD US score

11 (4–24)

  

ESR, mm/h

22 (11–35)

  

CRP, mg/L

6 (2–12)

  

Calprotectin, ng/ml

1149 (698–1949)

560 (412–796)b

<0.001

S100A12, ng/ml

275 (142–463)

129 (75–222)

<0.001

IL-6, pg/ml

5.2 (2.1–10.8)

0.9 (0.2–1.6)

<0.001

VEGF, pg/ml

80.8 (42.8–161.8)

67.5 (45.6–108.0)

<0.08

  1. Abbreviations: RF Rheumatoid factor, anti-CCP Anti-cyclic citrullinated peptide, DMARD Disease-modifying anti-rheumatic drug, VAS Visual analogue scale, DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate, GS Greyscale, US Ultrasound, PD Power Doppler, VEGF Vascular endothelial growth factor, IL-6 Interleukin 6
  2. Data are median (interquartile range) for continuous variables and number (percent) for categorical variables
  3. aMean (±SD)
  4. bControl subjects are healthy blood donors (50 men and 50 women) analysed by the manufacturer CALPRO AS, Lysaker, Norway